Drugs / ASP3652
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT02034734 | Sep → Dec 2012 | — | Astellas Pharma Europe B.V. | Completed | No outcome recorded |
| Phase 1 | NCT01815684 | Aug → Dec 2012 | — | Astellas Pharma Europe B.V. | Completed | No outcome recorded |
| Phase 1 | NCT01958047 | Jul → Sep 2012 | — | Astellas Pharma Europe B.V. | Completed | No outcome recorded |
| Phase 1 | NCT02046798 | Jul → Aug 2012 | — | Astellas Pharma Europe B.V. | Completed | No outcome recorded |
| Phase 1 | NCT01797198 | Apr → Jun 2012 | — | Astellas Pharma Europe B.V. | Completed | No outcome recorded |
| Phase 1 | NCT02243657 | May 2009 → May 2010 | — | Astellas Pharma Europe B.V. | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT01613586 | May 2012 → Mar 2014 | interstitial cystitis | Astellas Pharma Europe B.V. | Completed | No outcome recorded |
| Phase 2 | NCT01391338 | Jun 2011 → Feb 2013 | chronic pain syndrome, chronic prostatitis | Astellas Pharma Inc | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP3652 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02243657 ↗ |
| Action | Inhibit | “ASP3652, a peripherally acting inhibitor of fatty acid amide hydrolase” PMID 32715381 ↗ Jul 2020 |
| Route | Oral | “In comparison with placebo, ASP3652 will be given in different dosages orally for 12 weeks.” NCT01391338 ↗ |